Latest News & Updates
Janssen Research & Development, LLC, has submitted a supplemental New Drug Application for ibrutinib (Imbruvica) as treatment for patients with Waldenström's macroglobulinemia (WM).
Substantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should be the standard of care
Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.
How Test Reimbursement Decisions Are Made: A Leader of Medicare’s MolDX Program Discusses Evaluation Process
Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.
It seems like big data is everywhere these days. It’s being touted as a solution for physicians and practices who would like to participate in Accountable Care Organizations (ACOs) and accountable care-like contracts with payers.
Latest Peer Exchange Discussions
H. Jack West, MD, discusses next-generation ALK inhibitors in development and approved for patients with non-small cell lung cancer. View Now
Panelists discuss the role of checkpoint inhibition in renal cell carcinoma, which appears to be less clear than in other tumor types due to a multitude of existing effective therapies. View Now
Brian Rini, MD, FACP, and Daniel Heng, MD, MPH, FRCPC, discuss potential new therapies in the treatment of renal cell carcinoma. View Now
Most Popular Right Now
Online CME Activities